Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 1/20 | 0.45 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.45 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.45 |
| ▸ | ABCG2 | Q9UNQ0 | 6/20 | 0.43 |
| ▸ | EGFR | P00533 | 10/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 5/20 | 0.42 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7128556 | 0.92 | EGFR (0.47) | FBP1EPHB2MKNK1ABCG2EGFR | |
| SCHEMBL7127863 | 0.85 | EGFR (0.57) | ABCG2EGFRABCB1ERBB2 | |
| SCHEMBL7126655 | 0.78 | FBP1 (0.46) | FBP1EPHB2MKNK1EGFRERBB2 | |
| SCHEMBL7241075 | 0.78 | KDR (0.61) | EPHB2ABCG2EGFRABCB1ERBB2 | |
| SCHEMBL7127191 | 0.77 | EGFR (0.65) | EGFRERBB2 | |
| SCHEMBL7237992 | 0.74 | EGFR (0.44) | ABCG2EGFRHDAC1ABCB1ERBB2 | |
| SCHEMBL7241725 | 0.74 | EGFR (0.63) | ABCG2EGFRABCB1ERBB2 | |
| SCHEMBL7128163 | 0.72 | EGFR (0.55) | EPHB2MKNK1ABCG2EGFRHDAC1 | |
| SCHEMBL7128555 | 0.72 | EGFR (0.47) | FBP1EPHB2MKNK1EGFRERBB2 | |
| SCHEMBL8489713 | 0.72 | EGFR (0.60) | EPHB2ABCG2EGFRABCB1ERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030087881-A1 | Irreversible inhibitors of tyrosine kinases | BRIDGES ALEXANDER JAMES (US) | 2003-05-08 | — | — | US | claimed |
| US-6153617-A | Irreversible bicyclic inhibitors of tyrosine kinases | WARNER-LAMBERT COMPANY (US) | 2000-11-28 | — | — | US | claimed |
| WO-1999006396-A1 | IRREVERSIBLE BICYCLIC INHIBITORS OF TYROSINE KINASES | WARNER-LAMBERT COMPANY (US) | 1999-02-11 | — | — | WO | claimed |
| US-20030087881-A1 | Irreversible inhibitors of tyrosine kinases | BRIDGES ALEXANDER JAMES (US) | 2003-05-08 | — | — | US | disclosed |
| US-6153617-A | Irreversible bicyclic inhibitors of tyrosine kinases | WARNER-LAMBERT COMPANY (US) | 2000-11-28 | — | — | US | disclosed |
| WO-1999006396-A1 | IRREVERSIBLE BICYCLIC INHIBITORS OF TYROSINE KINASES | WARNER-LAMBERT COMPANY (US) | 1999-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087881-A1 | Irreversible inhibitors of tyrosine kinases | ERBB2, ERBB3, LCK | FBP1 4232/4885EPHB2 320/4885MKNK1 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.